Clinical trial
Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer
NCT00115635 · Herlev Hospital, Other · Completed
Key facts
| NCT number | NCT00115635 |
|---|---|
| Title | Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer |
| Official title | A Phase I/II Study With Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer |
| Lead sponsor | Herlev Hospital, Other |
| Collaborators | Sanofi Industry Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, gemcitabine |
| Enrollment | 60 |
| Start date | Mar 1, 2005 |
| Completion | Jul 1, 2007 |
| First posted | Jun 24, 2005 |
| Last update posted | Oct 2, 2007 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: